The authors report two cases of patients with advanced gastroenteric carcinoma, which developed different cardiotoxicity patterns after the administration of cytotoxic drugs. The firsts patient showed a picture of dilatative cardiomyopathy with associated symptoms of angina pectoris and congestive heart failure; the second patient presented a cardiac arrhythmia after several administrations of S-fluorouracil. The possible mechanisms of these toxic effects, as well as the drug interactions are briefly discussed. Cardiotoxicity of cytotoxic drugs should be considered by oncologists even in patients with no previous history of cardiac disease.
Get full access to this article
View all access options for this article.
References
1.
BillinghamM.E., MasonK.W., BristowM.R., DanielsJ.R.: Anthracycline cardiomyopathy monitored by morphologic changes. Cancer Treat. Rep., 62: 865–872, 1978.
2.
BristowM.R., MasonJ.W., BillinghamM.E.: Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy and cardiac cathetherization. Ann. Intern. Med., 88: 168–175, 1978.
3.
BristowM.R., MasonJ.W., BillinghamM.E.: Dose effect and structure function relationship in doxorubicin cardiomopathy. Am. Heart. J., 102: 709–718, 1981.
4.
BuzdarA.U., LeghaS.S., TashimaC.K., HortobagyiG.N., Yong YapH., KrutchikA.N., LunaM.A., BlumenscheinG.R.: Adriamycin and mitomycin C: possible synergistic cardiotoxicity. Cancer Treat. Rep., 62: 1005–1008, 1978.
5.
CanobbioL., FassioT., GaspariniG., CarusoG., BarzanL., ComorettoR., BremaF., VillaniF.: Cardiac arrhythmia: possible complication from treatment with cisplatin. Tumori, 72: 201–204, 1986.
6.
GanzP.A., GoldB.S., TandronI.: Angina pectoris after doxorubicin and mitomycin therapy. Cancer Treat. Rep., 67: 98–99, 1983.
7.
HashimiL.A., KhalylM.F., SalemP.A.: Supraventricular tachycardia, a probable complication of platinum treatment. Oncology, 41: 174–175, 1984.
LabiancaR., BerettaG., ClericiM., FraschinP., LuporiniG.: Cardiac toxicity of 5-fluorouracil: a study on 1083 patients. Tumori, 68: 505–510, 1982.
10.
LavryM.J.R.: Cardiotoxicity of mitomycin C in man and animals. Cancer Treat. Rep., 63: 555, 1979.
11.
LefakE.A., PitheS., RosenheimJ.: A clinicopathologic analysis of adriamycin cardiotoxicity. Cancer, 32: 302–324, 1973.
12.
LeghaS.S., Ben aminR.S., McKayB., EwerM., WallaceS., ValdiviesoM., RasmussenL.S., BlumenscheinG.R., FreireichE.J.: Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann. Intern. Med., 96: 133–139, 1982.
13.
LeoneB., RabinovichM., FerrariC.R., BoyerJ., RossoH., StraussS.: Cardiotoxicity as a results of 5-fluorouracil therapy. Tumori, 71: 55–57, 1985.
14.
LewisW., KleinermanJ., PuszkinS.: Interaction of adriamycin in vitro with cardiac myofibrillar proteins. Circ. Res., 50: 547–553, 1982.
15.
MancusoL., BondiF., MarchiS., IaconaM.A., Di GregorioL.: Cardiac toxicity of 5-fluorouracil. Report of a case of spontaneous angina. Tumori, 72: 121–124, 1986.
16.
ManenteP., BuchbergerR., ValmachinoG., FiorettiD., Lo GiudiceC., GasparoniP., ConteN.: Cardiotossicità da 5-fluorouracile: descrizione di un caso clinico. Tumori, 66: 255–260, 1980.
